ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Realm Therapeutics shares halved after failure of Phase 2 study
pharmafile
August 16, 2018Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the experimental drug PR022 had failed to meet its primary endpoint in people with atopic dermatitis. -
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy
americanpharmaceuticalreview
May 18, 2018Mobilization of hematopoietic stem and progenitor cells (HSPCs) for the purpose of donor (allogeneic) transplantation after high-dose chemotherapy is currently performed using a 4-5 day treatment cycle with G-CSF and a 1-2 day apheresis procedure.
Pharma Sources Insight January 2025
